HISTORY, EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS OF ADVERSE EVENTS: DATA REVIEW


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite the fact that modern medicines are produced according to modern requirements, the problem of development of adverse reactions remains very relevant. The most common adverse reactions include gastrointestinal bleeding and allergic reactions. The development of the pharmacovigilance service allows one to control the frequency of such reactions and to identify new ones noted already with a wide use in the population.

Full Text

Restricted Access

About the authors

I. E Kozulina

Institute of Interdisciplinary Medicine

Email: kozulina@idm.institute
PhD, Allergologist-Immunologist, Head of the Department of Organizing Scientific Research and Pharmacovigilance Systems, Manager at the Department of Scientific Studies Moscow, Russia

A. B Danilov

Institute of Interdisciplinary Medicine

Moscow, Russia

V. V Andrianov

Institute of Interdisciplinary Medicine

Moscow, Russia

References

  1. Dave V. Current trends in Pharmacovigilance. J. Pharmacovigilance. 2013;1(2). http://dx.doi. org/10.4172/2329-6887.1000e104.
  2. Кантемирова Б.И., Тимофеева Н.В., Григанов В.И., Шилова А.А. Проблема нежелательных побочных реакций лекарственных средств. Астраханcкий медицинский журн. 2011;6(4):8-12.
  3. Лукина Ю.В., Дмитриева Н.А., Захарова А.В., и др. Нежелательные явления лекарственной терапии (первые результаты исследования по данным амбулаторного регистра Профиль). Рациональная фармакотерапия в кардиологии. 2016;12(3):306-13.
  4. Wester K., Jönsson A.K., Spigset O., et al. Incidence of fatal adverse drug reactions: a population based study. Br. J. Clin. Pharmacol. 2008;65(4):573-79. doi: 10.1111/j.1365-2125.2007.03064.x.
  5. Chan A., et al. Cost evaluation of adverse drug reaction in hospitalized patient in Taiwan: f prospective, descriptive, observational study. Curr Ther. Res. 2008;69(2). Doi: 101016/j. curtheres.2008.04.005.
  6. Sultana J., Cutroneo P. Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother. 2013; 4(Suppl. 1):73-7.
  7. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ. 2004;329:15-9.
  8. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reaction in hospitalized patients: meta-analysis of prospective studies. JAMA. 1998;279:1200-205.
  9. Makary M.A., Daniel M. Medical error the third leading cause of death in the US. BMJ. 2016;353:i2139.
  10. McBride W. Teratogen Thalidomide embryopathy. Teratol. 1977;16(1). Doi: 10.1002/ tera.1420160113.
  11. Lenz W. Thalidomide and congenital abnormalities. J. Lancet. 1962;1:45.
  12. Загородникова К.А. Организация мониторинга безопасности лекарственных средств в мире - методологические подходы. Тихоокеанский медицинский журнал. 2015; 1:12-5.
  13. World Health Organization Collaborating center for international drug monitoring. Adverse reaction terminology. 31 December 1991.
  14. Викторов А.П. Контроль за безопасностью лекарственных препаратов в мире и проблемы развития фармакологического надзора в Украине. Провизор. 2002;1:9-13.
  15. Лепахин В.К. Современное состояние проблемы безопасности лекарственных средств. Международное сотрудничество. Контроль безопасности лекарств: материалы семинара: всемирного национального конгресса «Человек и лекарство». М., 1998. С. 2-15.
  16. Нормативные правовые акты в сфере обращения лекарственных средств в рамках евразийского экономического союза. Фармаконадзор. Ремедиум. 2017;6:18.
  17. Edwards I.R., Biriell C. Harmonisation in pharmacovigilance. Drug safety. 1994; 10:93-102.
  18. Meyboom R.H.B., Lindquist M., Egberts A.C.G. An ABC of drug-related problems. Drug safety. 2000;22:415-23.
  19. Fattinger K., Roos M., Verge res P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br. J. Clin. Pharmacology. 2000;49:158-67.
  20. Bouvy J.C., De Bruin M.L., Koopmanschap M.A. Epidemiology of advers drug reactions in Europe: a review of recent observational studies. Drug safety. 2015;38:437-53. Doi: 10.1007/ s40264-015-0281-0.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies